Welcome to our dedicated page for Tandem Diabetes news (Ticker: TNDM), a resource for investors and traders seeking the latest updates and insights on Tandem Diabetes stock.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) is a global insulin delivery and diabetes technology company whose news flow centers on product innovation, regulatory milestones, financial performance, and corporate developments. The company manufactures and sells advanced automated insulin delivery systems, including the Tandem Mobi system and the t:slim X2 insulin pump, both featuring Control-IQ or Control-IQ+ hybrid closed-loop technology.
News updates for Tandem Diabetes Care often highlight regulatory and product announcements. Recent examples include FDA 510(k) clearance for the SteadiSet infusion set for up to seven days of use, FDA clearance for the Android version of the Tandem Mobi mobile app, and integration of the t:slim X2 pump with Abbott’s FreeStyle Libre 3 Plus continuous glucose monitoring sensor in the United States. The company also issues press releases on software and mobile app availability, such as the Tandem t:slim mobile app launch for Android and iOS users in Canada.
Investors and observers can also expect regular earnings and guidance updates. Tandem Diabetes Care reports quarterly financial results and provides full-year guidance, with related press releases and conference call details disclosed publicly. Additional news items cover corporate governance, such as the appointment of new board members and committee assignments, as well as certifications like ISO/IEC 27001:2022 for information security.
This news page for TNDM aggregates these types of announcements, including earnings releases, regulatory clearances, product compatibility updates, conference presentations, and technology rollouts. It provides a single location to follow how Tandem Diabetes Care’s insulin delivery systems, digital platforms, and global initiatives are evolving over time.
Tandem Diabetes Care (Nasdaq: TNDM) announced that the Tandem Mobi automated insulin delivery system now pairs with compatible Android smartphones in the U.S. via the Tandem Mobi mobile app. The Android app received FDA clearance in November 2025 and had a limited release in December 2025.
The app is available on Google Play for compatible devices, including Google Pixel 6–10 and Samsung Galaxy S21–S25, expanding patient choice and connected-care accessibility.
Tandem Diabetes Care (NASDAQ: TNDM) priced an upsized private placement of $265.0 million 0.00% convertible senior notes due March 15, 2032, expected to close February 27, 2026. Net proceeds are estimated at $256.7 million (or $290.7 million if option exercised).
The notes convert at 27.0362 shares per $1,000 principal (≈ $36.99 per share), a ~37.5% premium to the Feb 24, 2026 share price; Tandem entered capped call transactions with an initial cap price of $47.075.
Tandem Diabetes Care (NASDAQ: TNDM) intends to sell $200.0 million aggregate principal amount of Convertible Senior Notes due 2032 in a private placement, with an option to sell an additional $30.0 million. Notes are unsecured, interest-bearing, convertible into cash, stock, or both.
Proceeds are expected to pay capped call transaction costs and for general corporate purposes, possibly including acquisitions, working capital, operating expenses and capital expenditures.
Tandem Diabetes Care (Nasdaq: TNDM) reported record Q4 sales of $290.4M and full‑year 2025 worldwide sales of $1.015B. Q4 gross margin reached 58%; full‑year gross margin was 54%. Full‑year shipments exceeded 126,000 pumps. Q4 operating income was $8.3M; full‑year GAAP net loss was $204.7M. Adjusted EBITDA for 2025 was a negative $46.1M. For 2026 the company guided sales of $1.065B–$1.085B, ~10%–11% shipment growth, gross margin ~56%–57%, and adjusted EBITDA margin ~5%–6%, while noting pay‑as‑you‑go and direct transition headwinds.
Tandem Diabetes Care (Nasdaq: TNDM) announced management will present company updates at three investor conferences in Feb–Mar 2026: Citi Unplugged MedTech on Feb 26, 2026 at 1:45pm ET, TD Cowen on Mar 4, 2026 at 9:10am ET, and Oppenheimer on Mar 18, 2026 at 1:20pm ET.
All presentations will be webcast live and archived for 30 days on the company's Investor Center under "Events & Presentations."
Tandem Diabetes Care (Nasdaq: TNDM) will release its fourth quarter and full year 2025 financial results after market close on Thursday, February 19, 2026. The company will host a conference call and simultaneous webcast the same day at 4:30 PM ET (1:30 PM PT) to discuss financial and operating results.
Investors can access the live webcast and an archived recording (available for 30 days) via Tandem Diabetes Care’s Investor Center under “Events & Presentations.” Telephone access and dial-in details are provided after registration through the company’s listed registration link.
Tandem Diabetes Care (Nasdaq: TNDM) announced on December 18, 2025 that the Tandem t:slim mobile app is now available in Canada for Android and iOS. The app lets eligible t:slim X2 users (pump version 7.8.1+) deliver and cancel boluses from a paired smartphone, view 24-hour glucose trends, pump status, basal/bolus deliveries and suspensions, and receive pump alerts. Data can be uploaded wirelessly to the cloud-based Tandem Source platform. The t:slim X2 pump continues to operate independently, and uploads are not real-time.
Tandem Diabetes Care (Nasdaq: TNDM) announced the appointment of Sandra Beaver to its board of directors effective November 7, 2025. Ms. Beaver joins as an independent director and will serve on the board’s Audit Committee and Cybersecurity and Data Oversight Committee. She brings more than 20 years of strategic and operational finance experience across healthcare, medical devices, enterprise technology, gaming and manufacturing. Ms. Beaver is currently CFO at Lyra Health (since June 2025) and previously served three years as CFO at Evolus, with prior senior finance roles at Experian and IGT. Her credentials include a Bachelor of Business Administration from University of Massachusetts and a Professional Designation in Relational Database Design from UCLA.
Tandem Diabetes Care (Nasdaq: TNDM) announced FDA clearance of the Android version of the Tandem Mobi mobile app, expanding compatibility to Android smartphones and extending its connected-care ecosystem.
Key facts: the app pairs with the Tandem Mobi automated insulin delivery system powered by Control-IQ+, cites outcomes including 79% time in range and 90% overnight time in range, and will begin a limited release in December 2025 with commercial availability in early 2026. Compatible devices slated to include Google Pixel 6–10 and Samsung Galaxy S21–S25; a full compatibility list will be published before launch.
Tandem Diabetes Care (Nasdaq: TNDM) reported Q3 2025 results on November 6, 2025, and reaffirmed full‑year 2025 guidance.
Key metrics: Q3 sales $249.3M worldwide with $73.6M outside the U.S.; U.S. shipments >20,000 pumps and international shipments >9,000 pumps. GAAP gross profit was $134.3M and GAAP gross margin improved to 54% from 51% year‑over‑year. GAAP net loss was $21.2M; GAAP operating loss was $22.9M (‑9% of sales). Adjusted EBITDA was $2.8M (1% of sales).
Operational progress: expanded pharmacy coverage for Tandem Mobi to >40% of U.S. lives, introduced t:slim X2 supplies via pharmacy, received FDA 510(k) for SteadiSet extended wear, filed 510(k) for Android control of Tandem Mobi, and began global rollout of t:slim X2 with FreeStyle Libre 3 Plus CGM.
Full‑year 2025 guidance: ~$1.0B sales (U.S. ~ $700M; non‑U.S. ~ $300M), gross margin ~53%–54%, and adjusted EBITDA margin ~‑5% (guidance recast to include an IPR&D charge).